Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
18 results
Search Results
Item The Health Impact Projection Model Of The Pd-1/Pd-L1 Inhibitor Class In Cancer Care In Turkey(2022) Akpamuk, U.; Hughes, R.; Swales, O.; Oyan, B.; Kilickap, S.; Demirci, U.; Sendur, M.A.; Sonmez, O.; Yazici, O.; Malhan, S.; Oksuz, E.; Tuzer, E.; Ersoy, Akyol B.; Poellinger, B.Item Economic Burden Of Migraine In Turkey(2022) Malhan, S.; Baykan, B.; Ertas, M.; Karli, N.; Oksuz, E.; Ozge, A.Item Economic Burden of Severe Asthma in Turkey: A Cost of Illness Study from Payer Perspective(2021) Bavbek, S.; Malhan, S.; Mungan, D.; Misirligil, Z.; Erdinc, M.; Gemicioglu, B.; Oguzulgen, I. Kivilcim; Oksuz, E.; Yildiz, F.; Yorgancioglu, A.; 0000-0002-5723-5965; 32372589; K-8238-2012Objective. To estimate economic burden of severe asthma in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods. This cost of illness study was based on identification of per patient annual direct medical costs for the management of severe asthma in Take, from payer perspective. Average per patient direct medical cost was calculated based on cost items related to outpatient visits laboratory and radiological tests, hospitalizations and interventions drug treatment and equipment, and co-morbidities/complications. Results. Based on total annual per patient costs calculated for outpatient admission ($177.91), laboratory and radiological tests ($ 8232), hospitalization/interventions ($1,154.55), drug treatment/equipment ($2,289.63) and co-morbidities ($ 661.39) cost items, total per patient annual direct medical cost related to management of severe asthma was calculated to be $ 4,369.76 from payer perspective. Drug treatment/equipment (524%) was the main cost driver in the management of severe asthma in Turkey, as followed by hospitalizations/interventions (264%) and co-morbidities (15.2%). Conclusions. In conclusion, our findings indicate that managing patients with severe asthma pose a considerable burden to health economics in Turkey with medications as the main cost driver.Item NATIONAL BURDEN OF HEMOPHILIA A IN TURKEY(2019) Malhan, S.; Oksuz, E.; Antmen, B.; Ar, C.; Balkan, C.; Kavakli, K.; 0000-0002-5723-5965; K-8238-2012Item COST MINIMIZATION ANALYSIS OF EMICIZUMAB IN THE PROPHYLAXIS OF INHIBITOR-NEGATIVE PATIENTS WITH HEMOPHILIA A IN TURKEY(2019) Guler, B.; Oksuz, E.; Malhan, S.; Yanik, L.; Koc, E.; 0000-0002-5723-5965; K-8238-2012Item THE EFFECTS OF REFORMS, PRICE CUTS AND GLOBAL BUDGET IMPLEMENTATION ON ORIGINAL/GENERIC MEDICINE SALES WHICH HAVE ANNUAL AVERAGE HIGHEST AMOUNT OF SALES BETWEEN 2008-2013 IN TURKEY(2014) Vural, I.M.; Vural, E.H.; Yiğit, O.; Dogan, E.; Babacan, S.; Tolun, C.; Uman, N.; Akbulat, A.; Malhan, S.; Kahveci, R.; Artiran, G.; Kerman, S.; 27201007Item THE EFFECTS OF REFORMS, PRICE CUTS AND GLOBAL BUDGET IMPLEMENTATION ON BIOTECHNOLOGICAL MEDICINE SALES WHICH HAVE ANNUAL AVERAGE HIGHEST AMOUNT OF SALES BETWEEN 2008-2013 IN TURKEY(2014) Vural, E.H.; Vural, I.M.; Yiğit, O.; Uman, N.; Tolun, C.; Babacan, S.; Dogan, E.; Akbulat, A.; Kahveci, R.; Malhan, S.; Artiran, G.; Kerman, S.; 27200997Item EFFECTS OF REFERENCE PRICE SYSTEM ON MEDICINES WHICH HAVE ANNUAL AVERAGE HIGHEST AMOUNT OF SALES OF BETWEEN YEARS 2008-2013(2014) Uman, N.; Tolun, C.; Babacan, S.; Dogan, E.; Vural, I.M.; Dasdag, M. M.; Yilmaz, Safak E.; Malhan, S.; Kahveci, R.; Akbulat, A.; Artiran, G; Kerman, S.; 27201003Item THE DIRECT COST OF ASTHMA IN TURKEY(2014) Turktas, H.; Bavbek, S.; Malhan, S.; 27202030Item Estimation of the Cost of Childhood Asthma in Turkey(2014) Sekerel, B.; Malhan, S.; 27202032